Medicus Pharma (MDCX) Expected to Announce Quarterly Earnings on Monday

Medicus Pharma (NASDAQ:MDCX) is anticipated to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Medicus Pharma Price Performance

Shares of NASDAQ:MDCX opened at $0.51 on Monday. Medicus Pharma has a 1 year low of $0.37 and a 1 year high of $8.94. The company has a market capitalization of $13.00 million, a PE ratio of -0.24 and a beta of -1.60. The business has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $1.76.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Medicus Pharma during the 2nd quarter worth $41,000. Osaic Holdings Inc. raised its stake in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after acquiring an additional 9,000 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Medicus Pharma during the third quarter valued at about $59,000. HRT Financial LP bought a new position in Medicus Pharma during the fourth quarter worth about $42,000. Finally, Commonwealth Equity Services LLC boosted its position in Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MDCX shares. D. Boral Capital reissued a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medicus Pharma presently has an average rating of “Hold” and a consensus price target of $23.50.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.